✦ LIBER ✦

Diarrheic syndrome as a clinical sign of intestinal infiltration in progressive B-cell chronic lymphocytic leukemia

✍ Scribed by E. Abella; T. Gimenez; J. Gimeno; M. Cervera; C. Pedro; E. Gimeno; A. Alvarez; A. Salar; B. Bellosillo; S. Serrano; C. Besses

Publisher: Elsevier Science
Year: 2009
Tongue: English
Weight: 610 KB
Volume: 33
Category: Article
ISSN: 0145-2126
DOI: 10.1016/j.leukres.2008.03.023

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Arthritis of the knees in b cell chronic

Arthritis of the knees in b cell chronic lymphocytic leukemia: a patient with immunologic evidence of b lymphocytic synovial infiltration

✍ Frédéric Gagnerie; Bruno Taillan; Liana Euller-Ziegler; Jean Kermarec; Francisqu 📂 Article 📅 1988 🏛 John Wiley and Sons 🌐 English ⚖ 248 KB 👁 2 views

Progression of a human B cell chronic ly

Progression of a human B cell chronic lymphocytic leukemia line in nude mice

✍ Dr. T. Ghose; C. L. Y. Lee; G. Faulkner; L. A. Fernandez; S. H. S. Lee 📂 Article 📅 1988 🏛 John Wiley and Sons 🌐 English ⚖ 1023 KB

Fc receptor-like 1–5 molecules are simil

Fc receptor-like 1–5 molecules are similarly expressed in progressive and indolent clinical subtypes of B-cell chronic lymphocytic leukemia

✍ Tohid Kazemi; Hossein Asgarian-Omran; Mohammad Hojjat-Farsangi; Mahdi Shabani; A 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 French ⚖ 354 KB

## Abstract Fc receptor‐like (FCRL) 1–5 molecules are exclusively expressed in B‐cells and have recently been considered as potential targets for immunotherapy of B‐cell malignancies. In this study, the expression pattern of FCRL1–5 molecules was investigated in Iranian patients with B‐cell chronic

Expression of TCL-1 as a potential progn

Expression of TCL-1 as a potential prognostic factor for treatment outcome in B-cell chronic lymphocytic leukemia

✍ Rebekah L. Browning; Susan M. Geyer; Amy J. Johnson; Diane F. Jelinek; Renee C. 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 208 KB

TCL-1 expression is variable in CLL, and no study has examined its association with treatment response. We measured TCL-1 protein in CLL cells from 51 patients who then received pentostatin, cyclophosphamide, and rituximab. TCL-1 expression did not correlate with any pre-treatment characteristics. L

Increased T-cell reactivity to leukemic

Increased T-cell reactivity to leukemic B cells in chronic lymphocytic leukemia with change of stable disease to its progressive form

✍ Louis A. Fernandez; J. Michael MacSween; G. Ross Langley 📂 Article 📅 1981 🏛 John Wiley and Sons 🌐 English ⚖ 418 KB 👁 2 views

Routine clinical use of alemtuzumab in p

Routine clinical use of alemtuzumab in patients with heavily pretreated B-cell chronic lymphocytic leukemia : A nation-wide retrospective study in Austria

✍ Michael Fiegl; Andreas Falkner; Georg Hopfinger; Stefan Brugger; August Zabernig 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 250 KB 👁 1 views

## Abstract ## BACKGROUND. In previous studies, alemtuzumab demonstrated considerable activity in patients with previously treated B‐cell chronic lymphocytic leukemia (CLL), including fludarabine‐refractory disease. In this retrospective study, the authors evaluated the benefit of alemtuzumab mono